The Solana respiratory viral panel (RVP) combines two Solana respiratory assays, Solana Influenza A+B and Solana RSV + hMPV, to create a focused respiratory viral panel to detect and differentiate all four respiratory viruses (influenza A, influenza B, respiratory syncytial virus and human metapneumovirus) from a single patient sample. Test up to 6 patients at a time in just 45 minutes using Solana’s high-volume throughput.
Solana Influenza A+B and Solana RSV + hMPV each amplifies and detects viral RNA present in transport media containing nasopharyngeal or nasal swab specimens obtained from symptomatic patients.
The process buffer is universal between both kits, which allows testing for all four conditions using a single patient sample. Testing is done using two major steps: (1) specimen preparation, and (2) amplification and detection of target sequences specific to RSV, hMPV, influenza A and/or influenza B using isothermal Reverse Transcriptase – Helicase-Dependent Amplification (RT-HDA) in the presence of target-specific fluorescence probes which is performed in the Solana instrument.
Results are displayed on the touchscreen, can be saved to the instrument, printed, and are capable of being sent to the LIS and exported through one of Solana’s five USB ports. Manage de-identified data, in near real time for improved operational efficiencies, using the Power of Virena®, which is integrated directly into Solana.
Please see chart below for ordering information.
Contact us
The Solana respiratory viral panel (RVP) combines two Solana respiratory assays, Solana Influenza A+B and Solana RSV + hMPV, to create a focused respiratory viral panel to detect and differentiate all four respiratory viruses (influenza A, influenza B, respiratory syncytial virus and human metapneumovirus) from a single patient sample. Test up to 6 patients at a time in just 45 minutes using Solana’s high-volume throughput.
Solana Influenza A+B and Solana RSV + hMPV each amplifies and detects viral RNA present in transport media containing nasopharyngeal or nasal swab specimens obtained from symptomatic patients.
The process buffer is universal between both kits, which allows testing for all four conditions using a single patient sample. Testing is done using two major steps: (1) specimen preparation, and (2) amplification and detection of target sequences specific to RSV, hMPV, influenza A and/or influenza B using isothermal Reverse Transcriptase – Helicase-Dependent Amplification (RT-HDA) in the presence of target-specific fluorescence probes which is performed in the Solana instrument.
Results are displayed on the touchscreen, can be saved to the instrument, printed, and are capable of being sent to the LIS and exported through one of Solana’s five USB ports. Manage de-identified data, in near real time for improved operational efficiencies, using the Power of Virena®, which is integrated directly into Solana.
Please see chart below for ordering information.
Contact us
Ordering information | ||
Solana Respiratory Viral Panel Kit | ||
Catalog number | Description | Kit size / Case size |
M925 | 1 Solana Influenza A+B Assay test kit (48 tests) 1 Solana RSV + hMPV Assay test kit (48 tests) | 96 tests |
Solana Respiratory Viral Panel Control Set | ||
Catalog number | Description | Kit size / Case size |
M926 | Kit contains 1 Solana Influenza A+B Control Set and 1 Solana RSV + hMPV Assay Control Set | 20 mL |
Features & benefits
Universal buffer solution allows testing for all four viruses using a single patient sample.
This small, easy-to-use instrument is great for smaller labs by saving space and eliminating the need for dedicated molecular space and costly capital equipment.
Rapid method of isothermal nucleic acid amplification that does not require thermocycling with RT-HDA technology.
To access safety data sheets, package inserts, quick reference guides and all other technical and promotional materials, visit our technical documents library.
- Specifications
Product specifications | |
Sample type | Nasal swabs and nasopharyngeal swabs in transport media* obtained from patients symptomatic of respiratory infection Note: Influenza A+B specimens collected in Copan eSwab transport media are stable at 2° C to 8°C for up to 48 hours |
Time to results | Approximately 45 minutes |
Reagent storage conditions | Lysis and Reaction Tubes; 2˚C to 8˚C |
Controls storage conditions | 2°C to 8°C |
Sample preparation storage conditions | Specimens should be collected, transported, stored, and processed according to CLSI M41-A and stored at 2°C to 8°C until tested. Specimens collected in BD UTM, Remel M4, M4RT, M5, and M6 (3 mL), and Copan eSwab are stable at 2°C to 8°C for up to 9 days |
PPA (PCR) | RSV: 95.5% (95% CI 91.0% to 97.8%) hMPV: 95.6% (95% CI 89.1% to 98.3%) |
NPA (PCR) | RSV: 99.9% (95% CI 91.0% to 97.8%) hMPV: 99.8% (95% CI 99.6% to 99.9%) |
Influenza A: 96.7% (95% CI 95.4% to 97.7%) Influenza B: 98.9% (95% CI 98.2% to 99.4%) | |
LOD (RSV) | RSV A, A2 (VR-1540): 7.9x103 TCID50/mL RSV B, Wash/18537/62 (VR-1580): 3.9x102 TCID50/mL |
LOD (hMPV) | hMPV 16 Type A1, IA10-2003: 3.7x10² TCID50/mL hMPV 20 Type A2 IA14-2003 G gene: 1.2x104 TCID50/mL hMPV 5 Type B1, Peru3-2003: 3.8x10³ TCID50/mL hMPV 4 Type B2, Peru1-2002: 2.3x10³ TCID50/mL |
LOD (Influenza A) | A/Taiwan/42/06: 7.5x102 TCID50/mL A/California/07/2009: 4.7x102 TCID50/mL A/Texas/50/2012: 6.3x100 TCID50/mL |
LOD (Influenza B) | B/Brisbane/60/08: 8.5x101 TCID50/mL B/Massachusetts/2/2012: 3.3x101 TCID50/mL |
Related products
- View all
- By disease and condition